Connect Biopharma Holdings Ltd. has announced the expansion of its Board of Directors from six to seven members, appointing industry veteran Jim Schoeneck as a new director. Schoeneck brings over 40 years of experience in developing and commercializing medicines, and he currently serves as Chairman of the Board of Directors for FibroGen, Inc. and Calidi Biotherapeutics, Inc. His appointment is expected to aid in advancing the development and commercialization of rademikibart, a treatment for asthma and COPD.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.